The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis
Authors:
Open Access
- 1 April 2011
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 133 (2) , 221-238
Abstract
Myeloid-derived suppressor cells (MDSC) are important to the tumour microenvironment as they actively suppress the immune system and promote tumour progression and metastasis. These cells block T-cell activation in the tumour microenvironment, preventing anti-tumour immune activity. The ability of a treatment to alter the suppressive function of these cells and promote an immune response is essential to enhancing overall therapeutic efficacy. Interleukin-12 (IL-12) has the potential not only to promote anti-tumour immune responses but also to block the activity of cells capable of immune suppression. This paper identifies a novel role for IL-12 as a modulator of MDSC activity, with implications for IL-12 as a therapeutic agent. Treatment with IL-12 was found to alter the suppressive function of MDSC by fundamentally altering the cells. Interleukin-12-treated MDSC exhibited up-regulation of surface markers indicative of mature cells as well as decreases in nitric oxide synthase and interferon-γ mRNA both in vitro and in vivo. Treatment with IL-12 was also found to have significant therapeutic benefit by decreasing the percentage of MDSC in the tumour microenvironment and increasing the percentage of active CD8+ T cells. Treatment with IL-12 resulted in an increase in overall survival accompanied by a reduction in metastasis. The findings in this paper identify IL-12 as a modulator of immune suppression with significant potential as a therapeutic agent for metastatic breast cancer.Keywords
This publication has 73 references indexed in Scilit:
- Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and CysteineCancer Research, 2010
- Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cellsInternational Immunopharmacology, 2009
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma PatientsClinical Cancer Research, 2009
- Conditions That Diminish Myeloid-Derived Suppressor Cell Activities Stimulate Cross-Protective ImmunityInfection and Immunity, 2008
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasisBreast Cancer Research and Treatment, 2008
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectivesImmunological Reviews, 2008
- Endogenous IL-12 triggers an antiangiogenic program in melanoma cellsProceedings of the National Academy of Sciences, 2007
- The Terminology Issue for Myeloid-Derived Suppressor CellsCancer Research, 2007
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionJournal of Experimental Medicine, 2006